Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$4.1 million.

  • Cytek Biosciences' Gains from Investment Securities fell 19486.88% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year decrease of 70570.34%. This contributed to the annual value of -$5.2 million for FY2024, which is 2176.85% up from last year.
  • Per Cytek Biosciences' latest filing, its Gains from Investment Securities stood at -$4.1 million for Q3 2025, which was down 19486.88% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Gains from Investment Securities registered a high of $9.5 million during Q2 2025, and its lowest value of -$7.1 million during Q4 2024.
  • Moreover, its 5-year median value for Gains from Investment Securities was $460000.0 (2022), whereas its average is $2.4 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 1110060.67% in 2023, then plummeted by 41095.99% in 2024.
  • Cytek Biosciences' Gains from Investment Securities (Quarter) stood at $625000.0 in 2021, then dropped by 26.4% to $460000.0 in 2022, then tumbled by 403.48% to -$1.4 million in 2023, then crashed by 410.96% to -$7.1 million in 2024, then skyrocketed by 42.72% to -$4.1 million in 2025.
  • Its Gains from Investment Securities was -$4.1 million in Q3 2025, compared to $9.5 million in Q2 2025 and -$1.5 million in Q1 2025.